Fourth-generation folic acid active metabolite Quatrefolic® and micronized, microencapsulated iron Lipofer®: innovative approaches for iron and folic acid deficiencies in women (a review)

I. N. Kononova, E. Kareva, Y. Dobrokhotova
{"title":"Fourth-generation folic acid active metabolite Quatrefolic® and micronized, microencapsulated iron Lipofer®: innovative approaches for iron and folic acid deficiencies in women (a review)","authors":"I. N. Kononova, E. Kareva, Y. Dobrokhotova","doi":"10.32364/2618-8430-2022-5-1-18-27","DOIUrl":null,"url":null,"abstract":"To review up-to-date management algorithms for iron and folic acid deficiency in women of reproductive age, we selected relevant publications in the PubMed and Google Scholar databases (2012–2022). Current limitations of using peroral iron salts (malabsorption, poor adherence to treatment due to gastrointestinal adverse reactions, risks of oxidative stress, and ferroptosis resulting from iron overload) were prerequisites for developing innovative technology, Lipofer®. Lipofer® is a micronized and microencapsulated iron in a phospholipid coat which provides better absorption independent of hepcidin status and targeted iron delivery in tissues with minimization of adverse reaction risks. Limitations of using folic acid include low bioavailability in polymorphisms of folate cycle enzymes (dihydrofolate reductase/DHFR and methylenetetrahydrofolate reductase/MTHFR) which results in potential toxic effects of unmetabolized folic acid and abnormal homocysteine clearance (risk factors for vascular disorders and B12-deficiency anemia masking). These entities were prerequisites for the development of Quatrefolic®. Quatrefolic® is the glucosamine salt of (6S)-5-methyltetrahydrofolate, an active metabolite of folic acid with high solubility and bioavailability ready to enter the folate cycle without involving reductases. Quatrefolic® is safe and has no risks of overdosing or effects on B12-deficiency anemia diagnosis. A combination of two high-tech molecules is an innovative therapeutic tool for essential microelement requirements in women with high risks of iron and folic acid deficiencies. KEYWORDS: iron-deficiency anemia, ferric pyrophosphate, microencapsulated iron, liposomal form, Lipofer, neural tube defect, folic acid, polymorphism, Quatrefolic, glucosamine salt. FOR CITATION: Kononova I.N., Kareva E.N. Fourth-generation folic acid active metabolite Quatrefolic® and micronized, microencapsulated iron Lipofer®: innovative approaches for iron and folic acid deficiencies in women (a review). Russian Journal of Woman and Child Health. 2022;5(1):18–27 (in Russ.). DOI: 10.32364/2618-8430-2022-5-1-18-27.","PeriodicalId":34075,"journal":{"name":"RMZh Mat'' i ditia","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMZh Mat'' i ditia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2618-8430-2022-5-1-18-27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To review up-to-date management algorithms for iron and folic acid deficiency in women of reproductive age, we selected relevant publications in the PubMed and Google Scholar databases (2012–2022). Current limitations of using peroral iron salts (malabsorption, poor adherence to treatment due to gastrointestinal adverse reactions, risks of oxidative stress, and ferroptosis resulting from iron overload) were prerequisites for developing innovative technology, Lipofer®. Lipofer® is a micronized and microencapsulated iron in a phospholipid coat which provides better absorption independent of hepcidin status and targeted iron delivery in tissues with minimization of adverse reaction risks. Limitations of using folic acid include low bioavailability in polymorphisms of folate cycle enzymes (dihydrofolate reductase/DHFR and methylenetetrahydrofolate reductase/MTHFR) which results in potential toxic effects of unmetabolized folic acid and abnormal homocysteine clearance (risk factors for vascular disorders and B12-deficiency anemia masking). These entities were prerequisites for the development of Quatrefolic®. Quatrefolic® is the glucosamine salt of (6S)-5-methyltetrahydrofolate, an active metabolite of folic acid with high solubility and bioavailability ready to enter the folate cycle without involving reductases. Quatrefolic® is safe and has no risks of overdosing or effects on B12-deficiency anemia diagnosis. A combination of two high-tech molecules is an innovative therapeutic tool for essential microelement requirements in women with high risks of iron and folic acid deficiencies. KEYWORDS: iron-deficiency anemia, ferric pyrophosphate, microencapsulated iron, liposomal form, Lipofer, neural tube defect, folic acid, polymorphism, Quatrefolic, glucosamine salt. FOR CITATION: Kononova I.N., Kareva E.N. Fourth-generation folic acid active metabolite Quatrefolic® and micronized, microencapsulated iron Lipofer®: innovative approaches for iron and folic acid deficiencies in women (a review). Russian Journal of Woman and Child Health. 2022;5(1):18–27 (in Russ.). DOI: 10.32364/2618-8430-2022-5-1-18-27.
第四代叶酸活性代谢物Quatrefolic®和微胶囊化铁Lipofer®:治疗女性铁和叶酸缺乏症的创新方法(综述)
为了回顾育龄妇女铁和叶酸缺乏症的最新管理算法,我们选择了PubMed和谷歌Scholar数据库(2012-2022)中的相关出版物。目前使用经口铁盐的局限性(吸收不良、胃肠道不良反应导致的治疗依从性差、氧化应激风险以及铁超载导致的铁下垂)是开发创新技术Lipofer®的先决条件。Lipofer®是一种微粉化和微胶囊化的铁在磷脂涂层中,提供更好的吸收独立于hepcidin状态和靶向铁在组织中的输送,最大限度地减少不良反应风险。使用叶酸的局限性包括叶酸循环酶(二氢叶酸还原酶/DHFR和亚甲基四氢叶酸还原酶/MTHFR)多态性的生物利用度低,这导致未代谢叶酸的潜在毒性作用和异常的同型半胱氨酸清除(血管疾病和b12缺乏性贫血的危险因素)。这些实体是开发Quatrefolic®的先决条件。Quatrefolic®是(6S)-5-甲基四氢叶酸的葡萄糖胺盐,是叶酸的活性代谢物,具有高溶解度和生物利用度,无需还原酶即可进入叶酸循环。Quatrefolic®是安全的,没有过量服用的风险或对b12缺乏性贫血诊断的影响。两种高科技分子的组合是一种创新的治疗工具,用于治疗铁和叶酸缺乏症高风险女性的必需微量元素需求。关键词:缺铁性贫血、焦磷酸铁、微囊化铁、脂质体形态、脂质体、神经管缺损、叶酸、多态性、四叶酸、氨基葡萄糖盐。引用本文:Kononova I.N, Kareva e.n。第四代叶酸活性代谢物Quatrefolic®和微粉化、微胶囊化铁Lipofer®:女性铁和叶酸缺乏症的创新方法(综述)。俄罗斯妇幼卫生杂志,2022;5(1):18-27。DOI: 10.32364 / 2618-8430-2022-5-1-18-27。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.60
自引率
0.00%
发文量
14
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信